2023 年第一季度报告 证券代码：688273 证券简称：麦澜德 南京麦澜德医疗科技股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上年同 期增减变动幅度(%) | | --- | --- | --- | | 营业收入 | 109,123,102.86 | 46.34 | | 归属于上市公司股东的净利润 | 32,386,135.75 | 53.60 | | 归属于上市公司股东的扣除非 经常性损益的净利润 | 27,009,796.08 | 33.22 | | 经营 ...

Financial Performance - The company achieved a net profit attributable to shareholders of RMB 121,932,792.91 for the year 2022[5]. - As of December 31, 2022, the company's distributable profits amounted to RMB 159,130,322.56[5]. - The proposed cash dividend is RMB 8.00 per 10 shares, totaling RMB 80,000,000.00 (including tax) based on a total share capital of 100,000,000 shares[5]. - The company's operating revenue for 2022 was ¥376,889,359.63, representing a 10.32% increase compared to ¥341,642,519.62 in 2021[21]. - The net profit attributable to shareholders for 2022 was ¥121,932,792.91, a 3.00% increase from ¥118,383,026.54 in the previous year[21]. - The net profit after deducting non-recurring gains and losses decreased by 14.90% to ¥89,042,289.66 from ¥104,629,819.12 in 2021[21]. - The net cash flow from operating activities for 2022 was ¥126,672,322.96, down 14.75% from ¥148,596,983.83 in 2021[21]. - The total assets at the end of 2022 were ¥1,510,397,322.7, a 209.04% increase from ¥488,743,868.02 in 2021[21]. - The net assets attributable to shareholders increased by 271.55% to ¥1,350,590,124.8 from ¥363,499,744.36 in 2021[21]. - Basic earnings per share for 2022 were ¥1.4632, a decrease of 7.30% from ¥1.5784 in 2021[23]. Research and Development - The R&D expenditure as a percentage of operating revenue was 10.97%, slightly up from 10.90% in 2021[23]. - The company invested 41.34 million RMB in R&D, marking an 11.04% increase compared to the previous year, with a total of 127 R&D personnel, up 9.48%[35]. - The company submitted 40 patent and software copyright applications during the year, including 18 invention patents, and received 34 approvals, with 5 being invention patents[35]. - The company has developed a programmable waveform constant current stimulation technology, enhancing treatment precision for pelvic rehabilitation[59]. - The company has developed a new generation of focused ultrasound transducers, significantly improving lifespan and reliability[35]. - The company has launched a new magnetic stimulator specifically designed for pelvic floor rehabilitation, featuring a high pulse magnetic field strength and a wide stimulation frequency range, enhancing clinical efficiency[38]. - The company has developed a hand rehabilitation robot that combines cognitive training and motor rehabilitation, expanding its product offerings in the rehabilitation sector[62]. Market and Industry Trends - The medical device industry in China achieved a revenue of approximately 1,043.4 billion CNY in 2021, marking a year-on-year growth of about 17%[48]. - The rehabilitation medical device market in China is projected to reach 67 billion CNY by 2023, driven by an aging population and increasing chronic disease prevalence[49]. - The market for pelvic floor dysfunction (PFD) treatment is expanding, with a significant increase in the number of women seeking rehabilitation services[50][51]. - The infertility treatment market in China has over 50 million patients, representing 12.5% to 15% of the reproductive population, with projections indicating an increase to 18.2% by 2023[52]. - The overall rehabilitation medical market in China is expected to exceed 70 billion CNY by 2023, with a compound annual growth rate of no less than 20%[53]. - The company has identified a growing clinical demand for pelvic floor dysfunction treatments, with an estimated 200 million individuals affected in China[129]. Corporate Governance and Compliance - The company has established a governance structure that includes multiple committees to ensure compliance and effective management of operations[146]. - The company maintains strong operational norms and independence, with governance practices aligning with the requirements set by the China Securities Regulatory Commission[147]. - The company has not reported any significant differences in governance compared to regulatory requirements, ensuring compliance[147]. - The company has not faced any issues regarding independence from its controlling shareholders or related entities[147]. - The company has established a complete internal control management system, ensuring compliance with relevant laws and regulations, and promoting sustainable development[194]. - The company has successfully passed the ISO14001 environmental management system audit without any non-conformities identified[200]. Strategic Plans and Future Outlook - The company aims for a net profit growth rate of no less than 30%, 69%, 120%, and 186% from 2023 to 2026, based on the 2022 net profit as a baseline[139]. - The company plans to enhance its product line by focusing on cutting-edge technologies and improving existing products, particularly in pelvic rehabilitation and expanding into reproductive and sports rehabilitation[139]. - The company intends to actively develop new products and expand into new departments, particularly in pelvic and reproductive rehabilitation, while ensuring safety and effectiveness[143]. - The company plans to leverage capital market functions for resource integration through investments and acquisitions to enrich its product structure and expand market share[144]. - The company is focused on developing a closed-loop rehabilitation ecosystem, integrating various rehabilitation technologies for improved patient outcomes[141]. Dividend Policy - The company has established a cash dividend policy that prioritizes cash distribution, with a minimum cash dividend ratio of 20% of the distributable profit each year[184]. - The company’s cash dividend distribution is subject to the condition that there are no major investment plans or significant cash expenditures exceeding 30% of the latest audited net assets[183]. - The independent directors are responsible for reviewing and providing opinions on the dividend distribution proposals to ensure compliance with regulations and shareholder interests[185]. - The net profit attributable to shareholders for 2022 was 121,932,792.91 RMB, representing a payout ratio of approximately 106.62% of the net profit[192]. Environmental, Social, and Governance (ESG) Practices - The company has actively engaged in ESG practices, aiming to integrate ESG principles into its corporate culture and operations[195]. - The company has implemented strict waste management practices, ensuring proper disposal of hazardous waste through licensed third parties[199]. - The company has adhered to environmental regulations, with no administrative penalties related to environmental issues during the reporting period[197].

Financial Performance - The company's operating revenue for Q3 2022 was ¥115,186,131.26, representing a year-over-year increase of 50.57%[5] - Net profit attributable to shareholders was ¥51,426,902.34, reflecting a significant increase of 130.92% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses was ¥37,356,961.25, up by 83.59% year-over-year[5] - Basic and diluted earnings per share were both ¥0.6171, an increase of 107.83% compared to the previous year[6] - Total operating revenue for the first three quarters of 2022 reached ¥298,319,574.22, an increase of 29.4% compared to ¥230,608,968.46 in the same period of 2021[22] - Net profit for the first three quarters of 2022 was ¥106,187,655.26, representing a 35.7% increase from ¥78,268,957.94 in the same period of 2021[23] - The total comprehensive income for the third quarter of 2022 was approximately ¥106.19 million, an increase from ¥78.27 million in the same period of 2021, representing a growth of 35.7%[24] - Basic and diluted earnings per share for the third quarter of 2022 were both ¥1.2608, compared to ¥1.0339 in the previous year, reflecting a year-over-year increase of 21.9%[24] Assets and Equity - Total assets at the end of the reporting period reached ¥1,518,041,892.49, marking a 210.60% increase since the beginning of the year[6] - Shareholders' equity attributable to the parent company was ¥1,387,000,367.62, which is a 281.57% increase from the beginning of the year[6] - The company's total assets amounted to ¥1,518,041,892.49, compared to ¥488,743,868.02 in the previous year, indicating significant growth[18] - The equity attributable to shareholders of the parent company increased to ¥1,387,000,367.62 from ¥363,499,744.36, reflecting strong financial health[18] Cash Flow - The company reported cash flow from operating activities of ¥67,479,101.45, which decreased by 29.16% compared to the previous year[6] - Cash inflows from operating activities for the first three quarters of 2022 totaled approximately ¥347.26 million, up from ¥316.16 million in the same period of 2021, indicating a growth of 9.8%[27] - The net cash flow from operating activities for the first three quarters of 2022 was ¥67.48 million, down from ¥95.25 million in the previous year, showing a decline of 29.3%[27] - Cash inflows from investment activities for the first three quarters of 2022 amounted to approximately ¥1.13 billion, compared to ¥544.48 million in the same period of 2021, marking an increase of 107.5%[27] - The net cash flow from investment activities for the first three quarters of 2022 was negative at approximately -¥210.57 million, worsening from -¥186.42 million in the previous year[27] - Cash inflows from financing activities for the first three quarters of 2022 reached approximately ¥941.47 million, significantly higher than ¥632,800 in the same period of 2021[28] - The net cash flow from financing activities for the first three quarters of 2022 was approximately ¥915.52 million, a substantial improvement from -¥14.47 million in the previous year[28] - The ending balance of cash and cash equivalents as of the end of the third quarter of 2022 was approximately ¥1.04 billion, a significant increase from ¥44.19 million at the end of the previous year[28] Expenses and Investments - Research and development expenses totaled ¥9,831,937.28, accounting for 8.54% of operating revenue, a decrease of 2.96 percentage points year-over-year[6] - Research and development expenses for the first three quarters of 2022 were ¥27,977,297.55, compared to ¥25,579,109.77 in the same period of 2021, indicating a focus on innovation[22] - The company reported a significant increase in other income, totaling ¥28,676,090.67, compared to ¥14,630,666.94 in the previous year[22] Market and Operational Insights - The increase in revenue was primarily driven by expanded market demand and increased sales scale[11] - The company has maintained a consistent increase in prepayments, which rose to ¥11,125,819.93 from ¥4,771,646.46 year-over-year[15] - The company has not reported any significant changes in its operational strategies or market expansion plans during the reporting period[15] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[22] Shareholder Information - The total number of common shareholders at the end of the reporting period was 10,689, with no preferred shareholders reported[13] - The top ten unrestricted shareholders collectively hold significant stakes, with the largest being Shanghai Gao Yi Asset Management holding 444,000 shares[14] - The company has not disclosed any significant related party transactions or agreements among its major shareholders[14] Audit and Compliance - The company did not conduct an audit for the Q3 financial statements[4] - There were no audit opinions applicable for the quarter, indicating a straightforward financial reporting process[15] - The company reported a tax refund of approximately ¥10.56 million in the third quarter of 2022, compared to ¥7.72 million in the same period of 2021, reflecting a growth of 37.5%[27]